基本信息
views: 183
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
It has an extensive scientific productivity, with more than 230 scientific articles in indexed journals with a cumulative number of citations exceeding 5,000. He has extensive experience in supervising research work (master, doctorate and post-doctorate), including about 40 students, of whom 34 have already finished their theses. He is regularly invited to perform the role of reviewer,also belonging to the editorial board of several scientific journals. He has already received several national and international awards that reinforce the visibility and quality of the work he has been developing throughout his career.
He is Technical Director of ICNAS Produção (a company wholly owned by the University of Coimbra), having actively participated in obtaining the first radiopharmaceutical medicine developed and registered in Portugal (Fluodeoxyglucose [18F] UC). Its contribution to the development of the first medicinal Portuguese to be marketed (Eslicarbazepine Acetate; Antiepileptic; Zebinix®) and, more recently, the Opicapone (Antiparkinsonic; Ongentys®) [BIAL Laboratories].
Researcher and leader of the Pharmacology Group of the Centre for Neuroscience and Cell Biology (CNC) of the University of Coimbra, Amílcar Falcão is the author and co-author of several hundred scientific papers and publications. With several ongoing fundamental and applied research projects, with most of the funding supported by national and multinational pharmaceutical companies, his scientific activity has earned him several awards throughout his professional career, notably the "Eminent Sicentist of the Year - Clinical Pharmacology" (2006) and the "Almofariz Award - Person of the Year" (2008).
He was directly involved in the development of the first Portuguese medicine (Eslicarbazepine Acetate - Zebinix®) as a consultant for BIAL Laboratories.
He is Technical Director of ICNAS Produção (a company wholly owned by the University of Coimbra), having actively participated in obtaining the first radiopharmaceutical medicine developed and registered in Portugal (Fluodeoxyglucose [18F] UC). Its contribution to the development of the first medicinal Portuguese to be marketed (Eslicarbazepine Acetate; Antiepileptic; Zebinix®) and, more recently, the Opicapone (Antiparkinsonic; Ongentys®) [BIAL Laboratories].
Researcher and leader of the Pharmacology Group of the Centre for Neuroscience and Cell Biology (CNC) of the University of Coimbra, Amílcar Falcão is the author and co-author of several hundred scientific papers and publications. With several ongoing fundamental and applied research projects, with most of the funding supported by national and multinational pharmaceutical companies, his scientific activity has earned him several awards throughout his professional career, notably the "Eminent Sicentist of the Year - Clinical Pharmacology" (2006) and the "Almofariz Award - Person of the Year" (2008).
He was directly involved in the development of the first Portuguese medicine (Eslicarbazepine Acetate - Zebinix®) as a consultant for BIAL Laboratories.
Research Interests
Papers共 418 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
The Analystno. 14 (2024): 3815-3827
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2024): 118-130
HEALTHCAREno. 1 (2024): 57
ACTA PHARMACOLOGICA SINICA (2024)
BRITISH JOURNAL OF CLINICAL PHARMACOLOGYno. 4 (2024): 1066-1080
Ageing research reviewspp.102395-102395, (2024)
Biochemical Pharmacology (2024): 116184-116184
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn